According to the research report, the global adeno associated virus vector manufacturing market size is expected to touch USD 6.64 Billion by 2032, from USD 0.84 Billion in 2022, growing with a significant CAGR of 22.97% from 2023 to 2032.
The adeno associated virus vector manufacturing report offers a comprehensive study of the current state expected at the major drivers, market strategies, and key vendors’ growth. The report presents energetic visions to conclude and study the market size, market hopes, and competitive surroundings. The research also focuses on the important achievements of the market, research & development, and regional growth of the leading competitors operating in the market. The current trends of the global adeno associated virus vector manufacturing in conjunction with the geographical landscape of this vertical have also been included in this report.
The report offers intricate dynamics about different aspects of the global adeno associated virus vector manufacturing market, which aids companies operating in the market in making strategic development decisions. The study also elaborates on significant changes that are highly anticipated to configure growth of the global adeno associated virus vector manufacturing during the forecast period. It also includes a key indicator assessment that highlights growth prospects of this market and estimates statistics related to growth of the market in terms of value (US$ Mn) and volume (tons).
Sample Link @ https://www.precedenceresearch.com/sample/2865
Report Scope of the Adeno Associated Virus Vector Manufacturing Market:
| Report Coverage | Details |
| Market Size in 2023 | USD 1.03 Billion |
| Market Size by 2032 | USD 6.64 Billion |
| Growth Rate from 2023 to 2032 | CAGR of 22.97% |
| Largest Market | North America |
| Fastest-Growing Market | Asia-Pacific |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Segments Covered | By Scale of Operations, By Method, By Application, and By Therapeutic Area |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America and Middle East & Africa |
This study covers a detailed segmentation of the global adeno associated virus vector manufacturing market, along with key information and a competition outlook. The report mentions company profiles of players that are currently dominating the global adeno associated virus vector manufacturing market, wherein various developments, expansions, and winning strategies practiced and implemented by leading players have been presented in detail.
Key Players
- Roche
- Audentes Therapeutics
- WuXi AppTec
- BioMarin Pharmaceutical
- Oxford BioMedica
- YPOSKESI
- Sarepta Therapeutics
- GenScript
- Pfizer
- Audentes Therapeutics
- LifeSpan BioSciences, Inc.
Market Segmentation
By Scale of Operations
- Clinical
- Preclinical
- Commercial
By Method
- In Vivo
- In Vitro
By Application
- Vaccine
- Cell Therapy
- Gene Therapy
By Therapeutic Area
- Genetic Disorders
- Infectious Diseases
- Neurological Disorders
- Hematological Diseases
- Ophthalmic Disorders
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
Research Methodology
The research methodology adopted by analysts for compiling the global adeno associated virus vector manufacturing report is based on detailed primary as well as secondary research. With the help of in-depth insights of the market-affiliated information that is obtained and legitimated by market-admissible resources, analysts have offered riveting observations and authentic forecasts for the global market.
During the primary research phase, analysts interviewed market stakeholders, investors, brand managers, vice presidents, and sales and marketing managers. Based on data obtained through interviews of genuine resources, analysts have emphasized the changing scenario of the global market.
For secondary research, analysts scrutinized numerous annual report publications, white papers, market association publications, and company websites to obtain the necessary understanding of the global adeno associated virus vector manufacturing market.
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Adeno Associated Virus Vector Manufacturing Market
5.1. COVID-19 Landscape: Adeno Associated Virus Vector Manufacturing Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Adeno Associated Virus Vector Manufacturing Market, By Scale of Operations
8.1. Adeno Associated Virus Vector Manufacturing Market Revenue and Volume Forecast, by Scale of Operations, 2023-2032
8.1.1. Clinical
8.1.1.1. Market Revenue and Volume Forecast (2020-2032)
8.1.2. Preclinical
8.1.2.1. Market Revenue and Volume Forecast (2020-2032)
8.1.3. Commercial
8.1.3.1. Market Revenue and Volume Forecast (2020-2032)
Chapter 9. Global Adeno Associated Virus Vector Manufacturing Market, By Method
9.1. Adeno Associated Virus Vector Manufacturing Market Revenue and Volume Forecast, by Method, 2023-2032
9.1.1. In Vivo
9.1.1.1. Market Revenue and Volume Forecast (2020-2032)
9.1.2. In Vitro
9.1.2.1. Market Revenue and Volume Forecast (2020-2032)
Chapter 10. Global Adeno Associated Virus Vector Manufacturing Market, By Application
10.1. Adeno Associated Virus Vector Manufacturing Market Revenue and Volume Forecast, by Application, 2023-2032
10.1.1. Cell Therapy
10.1.1.1. Market Revenue and Volume Forecast (2020-2032)
10.1.2. Gene Therapy
10.1.2.1. Market Revenue and Volume Forecast (2020-2032)
Chapter 11. Global Adeno Associated Virus Vector Manufacturing Market, By Therapeutic Area
11.1. Adeno Associated Virus Vector Manufacturing Market Revenue and Volume Forecast, by Therapeutic Area, 2023-2032
11.1.1. Genetic Disorders
11.1.1.1. Market Revenue and Volume Forecast (2020-2032)
11.1.2. Infectious Diseases
11.1.2.1. Market Revenue and Volume Forecast (2020-2032)
11.1.3. Neurological Disorders
11.1.3.1. Market Revenue and Volume Forecast (2020-2032)
11.1.4. Hematological Diseases
11.1.4.1. Market Revenue and Volume Forecast (2020-2032)
11.1.5. Ophthalmic Disorders
11.1.5.1. Market Revenue and Volume Forecast (2020-2032)
Chapter 12. Global Adeno Associated Virus Vector Manufacturing Market, Regional Estimates and Trend Forecast
12.1. North America
12.1.1. Market Revenue and Volume Forecast, by Scale of Operations (2020-2032)
12.1.2. Market Revenue and Volume Forecast, by Method (2020-2032)
12.1.3. Market Revenue and Volume Forecast, by Application (2020-2032)
12.1.4. Market Revenue and Volume Forecast, by Therapeutic Area (2020-2032)
12.1.5. U.S.
12.1.5.1. Market Revenue and Volume Forecast, by Scale of Operations (2020-2032)
12.1.5.2. Market Revenue and Volume Forecast, by Method (2020-2032)
12.1.5.3. Market Revenue and Volume Forecast, by Application (2020-2032)
12.1.5.4. Market Revenue and Volume Forecast, by Therapeutic Area (2020-2032)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Volume Forecast, by Scale of Operations (2020-2032)
12.1.6.2. Market Revenue and Volume Forecast, by Method (2020-2032)
12.1.6.3. Market Revenue and Volume Forecast, by Application (2020-2032)
12.1.6.4. Market Revenue and Volume Forecast, by Therapeutic Area (2020-2032)
12.2. Europe
12.2.1. Market Revenue and Volume Forecast, by Scale of Operations (2020-2032)
12.2.2. Market Revenue and Volume Forecast, by Method (2020-2032)
12.2.3. Market Revenue and Volume Forecast, by Application (2020-2032)
12.2.4. Market Revenue and Volume Forecast, by Therapeutic Area (2020-2032)
12.2.5. UK
12.2.5.1. Market Revenue and Volume Forecast, by Scale of Operations (2020-2032)
12.2.5.2. Market Revenue and Volume Forecast, by Method (2020-2032)
12.2.5.3. Market Revenue and Volume Forecast, by Application (2020-2032)
12.2.5.4. Market Revenue and Volume Forecast, by Therapeutic Area (2020-2032)
12.2.6. Germany
12.2.6.1. Market Revenue and Volume Forecast, by Scale of Operations (2020-2032)
12.2.6.2. Market Revenue and Volume Forecast, by Method (2020-2032)
12.2.6.3. Market Revenue and Volume Forecast, by Application (2020-2032)
12.2.6.4. Market Revenue and Volume Forecast, by Therapeutic Area (2020-2032)
12.2.7. France
12.2.7.1. Market Revenue and Volume Forecast, by Scale of Operations (2020-2032)
12.2.7.2. Market Revenue and Volume Forecast, by Method (2020-2032)
12.2.7.3. Market Revenue and Volume Forecast, by Application (2020-2032)
12.2.7.4. Market Revenue and Volume Forecast, by Therapeutic Area (2020-2032)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Volume Forecast, by Scale of Operations (2020-2032)
12.2.8.2. Market Revenue and Volume Forecast, by Method (2020-2032)
12.2.8.3. Market Revenue and Volume Forecast, by Application (2020-2032)
12.2.8.4. Market Revenue and Volume Forecast, by Therapeutic Area (2020-2032)
12.3. APAC
12.3.1. Market Revenue and Volume Forecast, by Scale of Operations (2020-2032)
12.3.2. Market Revenue and Volume Forecast, by Method (2020-2032)
12.3.3. Market Revenue and Volume Forecast, by Application (2020-2032)
12.3.4. Market Revenue and Volume Forecast, by Therapeutic Area (2020-2032)
12.3.5. India
12.3.5.1. Market Revenue and Volume Forecast, by Scale of Operations (2020-2032)
12.3.5.2. Market Revenue and Volume Forecast, by Method (2020-2032)
12.3.5.3. Market Revenue and Volume Forecast, by Application (2020-2032)
12.3.5.4. Market Revenue and Volume Forecast, by Therapeutic Area (2020-2032)
12.3.6. China
12.3.6.1. Market Revenue and Volume Forecast, by Scale of Operations (2020-2032)
12.3.6.2. Market Revenue and Volume Forecast, by Method (2020-2032)
12.3.6.3. Market Revenue and Volume Forecast, by Application (2020-2032)
12.3.6.4. Market Revenue and Volume Forecast, by Therapeutic Area (2020-2032)
12.3.7. Japan
12.3.7.1. Market Revenue and Volume Forecast, by Scale of Operations (2020-2032)
12.3.7.2. Market Revenue and Volume Forecast, by Method (2020-2032)
12.3.7.3. Market Revenue and Volume Forecast, by Application (2020-2032)
12.3.7.4. Market Revenue and Volume Forecast, by Therapeutic Area (2020-2032)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Volume Forecast, by Scale of Operations (2020-2032)
12.3.8.2. Market Revenue and Volume Forecast, by Method (2020-2032)
12.3.8.3. Market Revenue and Volume Forecast, by Application (2020-2032)
12.3.8.4. Market Revenue and Volume Forecast, by Therapeutic Area (2020-2032)
12.4. MEA
12.4.1. Market Revenue and Volume Forecast, by Scale of Operations (2020-2032)
12.4.2. Market Revenue and Volume Forecast, by Method (2020-2032)
12.4.3. Market Revenue and Volume Forecast, by Application (2020-2032)
12.4.4. Market Revenue and Volume Forecast, by Therapeutic Area (2020-2032)
12.4.5. GCC
12.4.5.1. Market Revenue and Volume Forecast, by Scale of Operations (2020-2032)
12.4.5.2. Market Revenue and Volume Forecast, by Method (2020-2032)
12.4.5.3. Market Revenue and Volume Forecast, by Application (2020-2032)
12.4.5.4. Market Revenue and Volume Forecast, by Therapeutic Area (2020-2032)
12.4.6. North Africa
12.4.6.1. Market Revenue and Volume Forecast, by Scale of Operations (2020-2032)
12.4.6.2. Market Revenue and Volume Forecast, by Method (2020-2032)
12.4.6.3. Market Revenue and Volume Forecast, by Application (2020-2032)
12.4.6.4. Market Revenue and Volume Forecast, by Therapeutic Area (2020-2032)
12.4.7. South Africa
12.4.7.1. Market Revenue and Volume Forecast, by Scale of Operations (2020-2032)
12.4.7.2. Market Revenue and Volume Forecast, by Method (2020-2032)
12.4.7.3. Market Revenue and Volume Forecast, by Application (2020-2032)
12.4.7.4. Market Revenue and Volume Forecast, by Therapeutic Area (2020-2032)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Volume Forecast, by Scale of Operations (2020-2032)
12.4.8.2. Market Revenue and Volume Forecast, by Method (2020-2032)
12.4.8.3. Market Revenue and Volume Forecast, by Application (2020-2032)
12.4.8.4. Market Revenue and Volume Forecast, by Therapeutic Area (2020-2032)
12.5. Latin America
12.5.1. Market Revenue and Volume Forecast, by Scale of Operations (2020-2032)
12.5.2. Market Revenue and Volume Forecast, by Method (2020-2032)
12.5.3. Market Revenue and Volume Forecast, by Application (2020-2032)
12.5.4. Market Revenue and Volume Forecast, by Therapeutic Area (2020-2032)
12.5.5. Brazil
12.5.5.1. Market Revenue and Volume Forecast, by Scale of Operations (2020-2032)
12.5.5.2. Market Revenue and Volume Forecast, by Method (2020-2032)
12.5.5.3. Market Revenue and Volume Forecast, by Application (2020-2032)
12.5.5.4. Market Revenue and Volume Forecast, by Therapeutic Area (2020-2032)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Volume Forecast, by Scale of Operations (2020-2032)
12.5.6.2. Market Revenue and Volume Forecast, by Method (2020-2032)
12.5.6.3. Market Revenue and Volume Forecast, by Application (2020-2032)
12.5.6.4. Market Revenue and Volume Forecast, by Therapeutic Area (2020-2032)
Chapter 13. Company Profiles
13.1. Roche
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Audentes Therapeutics
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. WuXi AppTec
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. BioMarin Pharmaceutical
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Oxford BioMedica
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. YPOSKESI
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Sarepta Therapeutics
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. GenScript
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Pfizer
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Audentes Therapeutics
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
Chapter 14. Research Methodology
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
Chapter 15. Appendix
15.1. About Us
15.2. Glossary of Terms
Contact Us:
Precedence Research
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1 774 402 6168
Email: sales@precedenceresearch.com
Website: https://www.precedenceresearch.com
Blog: https://www.pharma-geek.com
0 Comments